Researchers have demonstrated that inebilizumab reduced the risk of symptoms by 87 percent in patients with the rare affliction known as immunoglobulin G4-related disease (IgG4-RD).

Current methods to deliver bacteria to the bladder are invasive and require repeated catheter insertion. Even when bacteria ...

InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced that the Committee for Medicinal Products for Human ...

RSV hospitalizations in US adults reached high levels pre-vaccine, especially impacting those 75 and older, underscoring the ...

SPR206 is an investigational, intravenously administered next-generation polymyxin that has shown antibiotic activity against MDR Gram-negative pathogens, including carbapenem-resistant ...

An international, Phase III clinical trial led by investigators at Mass General Brigham could improve the treatment of a rare ...

The AD risk factors/hits include high exposure to traffic-related air pollution (TRAP) and infections, as well as factors ...

One woman’s journey from receiving her diagnosis to finding a treatment that helps manage her chronic skin condition.

Advances in cardiac imaging techniques and risk categorization have led to improvements in diagnosis, initial treatment and ...

Bob Self/Florida Times-Union Bob Self/Florida Times-Union / USA TODAY NETWORK When the Centers for Disease Control and ...

A dermatophyte known as Trichophyton mentagrophytes genotype VII (TMVII) has been identified as the cause of an emerging ...

If you feel a cold coming on, the best way to support your immune system and symptoms is to hydrate and rest. Learn what ...